{"nctId":"NCT01167881","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes","startDateStruct":{"date":"2010-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":1549,"armGroups":[{"label":"BI 10773 dose plus metformin","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: Placebo"]},{"label":"Glimepiride 1-4 mg plus metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimepiride","Drug: Placebo"]}],"interventions":[{"name":"BI 10773","otherNames":[]},{"name":"Glimepiride","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Diagnosis typ 2 diabetes mellitus\n* Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks prior to randomisation\n* HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1\n* 18 years or more\n* BMI equal or less than 45Kg/m2\n\nExclusion criteria:\n\n* Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight fast during placebo run-in\n* Any other antidiabetic drug within 12 weeks prior to randomisation except metformin\n* Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or transient ischemic attack within 12 weeks of informed consent\n* Indication of liver disease\n* Moderate to severe renal impairment\n* Bariatric surgery within past 2 years\n* Medical history of cancer or treatment for cancer within last 5 years\n* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell\n* Contraindications hypersensitivity to concomitant drugs\n* Treatment with anti-obesity drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"The Change in Body Weight From Baseline After 104 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.11","spread":"0.13"},{"groupId":"OG001","value":"1.33","spread":"0.13"}]}]}]},{"type":"PRIMARY","title":"The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.03"},{"groupId":"OG001","value":"-0.55","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"0.5"},{"groupId":"OG001","value":"2.5","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.3"},{"groupId":"OG001","value":"0.9","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in HbA1c After 52 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"0.03"},{"groupId":"OG001","value":"-0.66","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"The Change in Body Weight From Baseline After 52 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.21","spread":"0.12"},{"groupId":"OG001","value":"1.59","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"0.5"},{"groupId":"OG001","value":"2.2","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.3"},{"groupId":"OG001","value":"1.0","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":161,"n":765},"commonTop":["Hyperglycaemia","Hypoglycaemia","Urinary tract infection","Upper respiratory tract infection","Nasopharyngitis"]}}}